Cell
An amazing sequence arrangement at the 5′ ends of adenovirus 2 messenger RNA
Abstract
The 5′ terminal sequences of several adenovirus 2 (Ad2) mRNAs, isolated late in infection, are complementary to sequences within the Ad2 genome which are remote from the DNA from which the main coding sequence of each mRNA is transcribed. This has been observed by forming RNA displacement loops (R loops) between Ad2 DNA and unfractionated polysomal RNA from infected cells. The 5′ terminal sequences of mRNAs in R loops, variously located between positions 36 and 92, form complex secondary hybrids with single-stranded DNA from restriction endonuclease fragments containing sequences to the left of position 36 on the Ad2 genome. The structures visualized in the electron microscope show that short sequences coded at map positions 16.6, 19.6 and 26.6 on the R strand are joined to form a leader sequence of 150–200 nucleotides at the 5′ end of many late mRNAs. A late mRNA which maps to the left of position 16.6 shows a different pattern of second site hybridization. It contains sequences from 4.9−6.0 linked directly to those from 9.6−10.9. These findings imply a new mechanism for the biosynthesis of Ad2 mRNA in mammalian cells.
References (33)
- L. Chow et al.
Cell
(1977) - A.R. Dunn et al.
Cell
(1977) - S.A. Endow et al.
J. Mol. Biol.
(1977) - R.E. Gelinas et al.
Cell
(1977) - G.S. Hayward
Virology
(1972) - R.B. Kelly et al.
J. Biol. Chem.
(1970) - D.F. Klessig
Cell
(1977) - B. Lewin
Cell
(1975) - B. Lewin
Cell
(1975) - J.B. Lewis et al.
Cell
(1977)
J. Mol. Biol.
J. Mol. Biol.
J. Mol. Biol.
J. Mol. Biol.
Anal. Biochem.
Cell
Cited by (752)
Understanding age-related pathologic changes in TDP-43 functions and the consequence on RNA splicing and signalling in health and disease
2024, Ageing Research ReviewsTAR DNA binding protein-43 (TDP-43) is a key component in RNA splicing which plays a crucial role in the aging process. In neurodegenerative diseases such as amyotrophic lateral sclerosis, frontotemporal dementia and limbic-predominant age-related TDP-43 encephalopathy, TDP-43 can be mutated, mislocalised out of the nucleus of neurons and glial cells and form cytoplasmic inclusions. These TDP-43 alterations can lead to its RNA splicing dysregulation and contribute to mis-splicing of various types of RNA, such as mRNA, microRNA, and circular RNA. These changes can result in the generation of an altered transcriptome and proteome within cells, ultimately changing the diversity and quantity of gene products. In this review, we summarise the findings of novel atypical RNAs resulting from TDP-43 dysfunction and their potential as biomarkers or targets for therapeutic development.
RNA splicing is a post-transcriptional event that regulates many physiological and pathological events. However, whether RNA splicing regulates cerebral I/R-induced brain injury remains largely unknown. In this study, we found that the chromatin target of Prmts (CHTOP) was highly expressed in neurons, and anti-inflammatory cytokine interleukin-10 (IL-10) upregulates its expression after ischemia. In addition, overexpression or knockdown of CHTOP alleviated or exacerbated neuronal death in both experimental stroke mice and cultured neurons. Mechanistically, RNA alternative splicing is altered early after oxygen and glucose deprivation/reoxygenation (OGD/R). CHTOP interacted with nuclear speckle-related proteins to regulate alternative mRNA splicing of neuronal survival-related genes after OGD/R. In addition, I/R injury-induced cytokines IL-10 regulate CHTOP-mediated RNA splicing to alleviate ischemic brain injury. Taken together, this study reveals the alteration of RNA splicing after OGD/R and identifies the IL-10-CHTOP-RNA splicing axis as a modulator of brain injury, which may be promising therapeutic targets for ischemic stroke.
RNA therapeutics history and future perspectives
2024, Progress in Molecular Biology and Translational ScienceRibonucleic acid (RNA) therapeutics have significantly used RNA-based drugs to the prevention and treatment of diseases as effective messenger RNA-based vaccines in response to the COVID-19 pandemic. The RNA therapeutics with five classes including antisense oligonucleotide, small interfering RNA, microRNA, APTAMER and messenger RNAs are being quickly developed to treat various human diseases as neurological disease, cardiovascular disease, genetic and rare disease, cancer disease, coronavirus disease… which cannot be treated by other conventional drugs as small molecule-based drugs and antibodies. Therefore, the discovery of these RNA therapeutics created a new avenue for treatment of various human diseases. This chapter demonstrates the history of important discoveries in RNA biology and their impact on key developments in RNA therapeutics as well as the advantages of RNA therapeutics; RNA therapeutics describes the action mechanisms and examples of RNA-based drugs approved for treatment of various disease; and RNA therapeutics discusses delivery methods for RNA therapeutics to target organs and cells. In conclusion, this chapter is designed to offer an updated important development and advance of RNA therapeutics for the prevention and treatment of various human diseases.
RNA therapeutics for disorders of excretory system
2024, Progress in Molecular Biology and Translational ScienceThe excretory system is responsible for removing wastes from the human body, which plays a crucial role in our lives. Current treatments for diseases related to this system have shown several limitations; therefore, there is a rising need for novel methods. In this circumstance, RNA-based therapeutics have rapidly emerged as new and promising candidates. In fact, to date, a handful of potential drugs have passed the development step and entered the clinical pipeline. Among them, one drug received FDA approval to enter the global market, which is Oxlumo (Lumasiran) for the treatment of primary hyperoxaluria type 1. For other excretory diseases, such as paroxysmal nocturnal hemoglobinuria, urothelial cancer or renal cancer, RNA-based candidates are also being tested under clinical trials. Currently, the most potential types of RNA therapeutics to treat disorders of the excretory system are those based on small interfering RNA (siRNA), antisense oligonucleotides (ASO) and messenger RNA (mRNA), Among them, siRNA therapeutics seem to be the most promising, including Oxlumo and two other developing drug candidates. This chapter will provide a general overview on the application of RNA therapeutics in disorders of the excretory system.
All differential on the splicing front: Host alternative splicing alters the landscape of virus-host conflict
2023, Seminars in Cell and Developmental BiologyAlternative RNA splicing is a co-transcriptional process that richly increases proteome diversity, and is dynamically regulated based on cell species, lineage, and activation state. Virus infection in vertebrate hosts results in rapid host transcriptome-wide changes, and regulation of alternative splicing can direct a combinatorial effect on the host transcriptome. There has been a recent increase in genome-wide studies evaluating host alternative splicing during viral infection, which integrates well with prior knowledge on viral interactions with host splicing proteins. A critical challenge remains in linking how these individual events direct global changes, and whether alternative splicing is an overall favorable pathway for fending off or supporting viral infection. Here, we introduce the process of alternative splicing, discuss how to analyze splice regulation, and detail studies on genome-wide and splice factor changes during viral infection. We seek to highlight where the field can focus on moving forward, and how incorporation of a virus-host co-evolutionary perspective can benefit this burgeoning subject.
Deployment of Intron Length Polymorphic (ILP) markers in dissipating diversity of Allium species
2023, South African Journal of BotanyAllium is one of the largest genera in monocots, it comprise of cultivated species like onion, garlic, leek, shallot, chive and bunching onion, and other semi-domesticated and wild species used as minor vegetables. Among species, the development and widespread of microsatellites have been reported, but there are least reports of systematic research and extensive use of intron-length polymorphic (ILP) markers among alliums. Introns endure less selection pressure, resulting in their polymorphism. Intron Length Polymorphic (ILP) markers derived from exon-flanking introns have been demonstrated to be accurate co-dominant markers in eukaryotes via the use of this polymorphism potential. In the present study, the genetic diversity aomong 95 accessions of alliums from the 13 species was revealed by ILP markers via UPGMA method, and population structure was also studied. Twenty-two ILP markers generated 75 loci with an average of 25.4 amplicons per loci. The Polymorphic Information content (PIC) ranges from 0.02 – 0.99, which is the lowest to highest polymorphic marker. The clustering pattern revealed the population, which were grouped into three major clusters, such as major cluster I grouped by semi-domesticated and wild species, major cluster II consist of cultivated Allium species (onion, garlic, and bunching onions) and major cluster III was out grouped which consisted of genotypes belong to Allium hookeri. The population structure studied also revealed the highest ΔK at 3, which inferred that the population was grouped into 3 genetic groups, which were correlated to the UPGMA clustering. From the finding of the diversity and phylogenetic relationship among the Allium species could be employed in further breeding programs for genetic improvement through inter-specific hybridization, to introgress the desirable traits from semi domesticated to the cultivated species.